3 results
To assess safety, tolerability, and PK of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and Budigalimab in subjects with R/M HNSCC.
The study includes 2 periods, Period 1 and Period 2. Subjects will participate in both periods. Period 1:The purpose of Period 1 is to investigate how quickly and to what extent enpatoran is absorbed, transported and eliminated from the body (this…
Primary objective:To evaluate the efficacy of cobolimab + dostarlimab + docetaxel relative to docetaxel alone in participants with advanced NSCLC who have progressed on prior anti-PD-(L)1 therapy andChemotherapy.To evaluate the efficacy of…